

Annual Report
Novel Therapies Committee
May, 2019

The Novel Therapies Committee is a new committee, struck in early 2019 at the request of the Executive. Jerry Teitel was asked to serve as the initial Chair, and to propose members to join the committee. Drs. Adrienne Lee, Margaret Warner, Jayson Stoffman, and Mark Belletrutti agreed to join the committee.

An initial teleconference was held on March 6, 2019 to consider terms of reference and possible projects. The TOR have been drafted and are now being considered by the members, for presentation to the Executive.

The first project of the Committee will be to join with the Inhibitor Committee in its project (already underway) to provide guidance to AHCDC members on the introduction of emicizumab into clinical use in Canada.

Other projects to be considered by the Committee in the near future will relate to licensed products about to enter the clinic, such as recombinant VWF and recombinant porcine FVIII, and potential participation by Canadian sites in research into promising new therapies such as novel molecules and gene-based therapies.

Jerry Teitel
Chair